• Vera Therapeutics posted a net loss of USD 109.5 million, or USD 1.52 per share, in Q2 2026, widening from a loss of USD 76.5 million.
• Net cash used in operating activities totaled USD 206.8 million for the six months ended June 30, 2026.
• Cash, cash equivalents and marketable securities were USD 499.2 million as of June 30, 2026; up to USD 425 million remained available under its debt facility.
• TRUTAKNA won FDA accelerated approval in adult primary IgA nephropathy patients at risk of progression; U.S. launch is underway.
• ORIGIN 3 final efficacy analysis is expected in Q3 2026; an sBLA submission is targeted for Q4 2026, with potential full approval expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vera Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-26-342335), on August 10, 2026, and is solely responsible for the information contained therein.